Changzhou Qianhong Biopharma CO.,LTD (SHE:002550)
7.09
-0.02 (-0.28%)
Apr 29, 2026, 3:04 PM CST
SHE:002550 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Net Income | 297.34 | 373.25 | 356.03 | 181.86 | 323.41 | 181.08 | Upgrade
|
| Depreciation & Amortization | 65.9 | 65.9 | 64.61 | 69.22 | 64.76 | 69.43 | Upgrade
|
| Other Amortization | 3.91 | 3.91 | 5.27 | 3.75 | 3.55 | 5.67 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.01 | -0.01 | - | -25.35 | -57.59 | - | Upgrade
|
| Asset Writedown & Restructuring Costs | -116.23 | -116.23 | 0.04 | 7.77 | 0.24 | 0.46 | Upgrade
|
| Loss (Gain) From Sale of Investments | -11.59 | -11.59 | -13.89 | -8.83 | 3.82 | -0.64 | Upgrade
|
| Provision & Write-off of Bad Debts | - | - | 6.04 | -19.02 | 15.3 | -52.68 | Upgrade
|
| Other Operating Activities | 157.24 | 14.58 | -101.48 | 19.11 | -46.62 | 6.11 | Upgrade
|
| Change in Accounts Receivable | -37.84 | -37.84 | -12.26 | 420.4 | -165.9 | 55.37 | Upgrade
|
| Change in Inventory | 49.07 | 49.07 | 172.11 | -77.46 | -136.12 | -84.79 | Upgrade
|
| Change in Accounts Payable | 12.92 | 12.92 | 24.09 | -50.63 | -83.14 | -86.65 | Upgrade
|
| Change in Other Net Operating Assets | -2.09 | -2.09 | -0.62 | 1.98 | 4.37 | 4.12 | Upgrade
|
| Operating Cash Flow | 428.11 | 361.36 | 514.71 | 533.33 | -71.47 | 103.56 | Upgrade
|
| Operating Cash Flow Growth | 3.13% | -29.79% | -3.49% | - | - | -67.36% | Upgrade
|
| Capital Expenditures | -166.6 | -141.6 | -90.64 | -100.33 | -70.99 | -90.37 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.09 | 0.09 | 13.5 | 32.3 | 0.11 | 0 | Upgrade
|
| Cash Acquisitions | - | - | - | - | -1.67 | - | Upgrade
|
| Investment in Securities | 142.69 | 142.69 | -232.15 | -108.5 | -121.08 | 177.22 | Upgrade
|
| Other Investing Activities | -259.72 | -163.52 | -13.94 | 1.43 | 3.65 | 8.43 | Upgrade
|
| Investing Cash Flow | -283.54 | -162.34 | -323.23 | -175.1 | -189.98 | 95.28 | Upgrade
|
| Short-Term Debt Issued | - | - | 4.69 | 435.51 | 461.27 | 124.95 | Upgrade
|
| Total Debt Issued | - | - | 4.69 | 435.51 | 461.27 | 124.95 | Upgrade
|
| Short-Term Debt Repaid | - | - | -40.1 | -480 | -440 | -77.43 | Upgrade
|
| Long-Term Debt Repaid | - | -20 | - | - | - | - | Upgrade
|
| Total Debt Repaid | -20 | -20 | -40.1 | -480 | -440 | -77.43 | Upgrade
|
| Net Debt Issued (Repaid) | -20 | -20 | -35.41 | -44.49 | 21.27 | 47.52 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 144.9 | - | Upgrade
|
| Repurchase of Common Stock | - | - | -140.77 | -30.09 | - | -0.19 | Upgrade
|
| Common Dividends Paid | -149.76 | -150.43 | -151.52 | -158.79 | -155.16 | -151.51 | Upgrade
|
| Other Financing Activities | 78.88 | 32.76 | 3 | 42.5 | - | - | Upgrade
|
| Financing Cash Flow | -90.87 | -137.68 | -324.71 | -190.87 | 11.02 | -104.17 | Upgrade
|
| Foreign Exchange Rate Adjustments | -14.75 | -13.05 | -1.85 | -1.6 | 41.89 | 7.39 | Upgrade
|
| Net Cash Flow | 38.95 | 48.29 | -135.07 | 165.76 | -208.55 | 102.06 | Upgrade
|
| Free Cash Flow | 261.51 | 219.76 | 424.07 | 433 | -142.46 | 13.19 | Upgrade
|
| Free Cash Flow Growth | -16.02% | -48.18% | -2.06% | - | - | -94.82% | Upgrade
|
| Free Cash Flow Margin | 17.69% | 13.99% | 27.79% | 23.87% | -6.18% | 0.70% | Upgrade
|
| Free Cash Flow Per Share | 0.21 | 0.18 | 0.33 | 0.33 | -0.11 | 0.01 | Upgrade
|
| Cash Income Tax Paid | 155.77 | 156.06 | 150.65 | 45.16 | 26.55 | 81.87 | Upgrade
|
| Levered Free Cash Flow | 482.76 | 122.01 | 334.4 | 344.34 | -216.74 | -40.56 | Upgrade
|
| Unlevered Free Cash Flow | 482.76 | 122.01 | 335.27 | 348.04 | -213.46 | -39.53 | Upgrade
|
| Change in Working Capital | 31.55 | 31.55 | 198.09 | 304.81 | -378.36 | -105.88 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.